Methods for treatment using adoptive cell therapy

A method of treating a subject having or suspected of having a primary central nervous system lymphoma (PCNSL), the method comprising administering to a subject a dose of T cells comprising cells expressing a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular antigen-binding domain that specifically binds to CD19, wherein:

• the CAR comprises the extracellular antigen-binding domain, a spacer, a transmembrane domain, and an intracellular signaling domain comprising a 4-1BB costimulatory signaling domain and a CD3zeta signaling domain;
• the extracellular antigen-binding domain is an scFv that is derived from FMC63;
• the CAR comprises a CDRL1 sequence of RASQDISKYLN (SEQ ID NO:35), a CDRL2 sequence of SRLHSGV (SEQ ID NO:36), a CDRL3 sequence of GNTLPYTFG (SEQ ID NO:37), a CDRH1 sequence of DYGVS (SEQ ID NO:38), a CDRH2 sequence of VIWGSETTYYNSALKS (SEQ ID NO:39), and a CDRH3 sequence of YAMDYWG (SEQ ID NO:40);
• the dose of T cells comprises between at or about 2.5×107 viable CD19 CAR-expressing T cells and at or about 2×108 viable CD19 CAR-expressing T cells, inclusive;
• and
• the dose of T cells comprises CD19 CAR-expressing CD4+ T cells and CD19 CAR-expressing CD8+ T cells.